Allergan plc AGN along with Hungary’s Gedeon Richter Plc announced that the FDA has approved a supplemental new drug application (sNDA) of its schizophrenia drug, Vraylar (cariprazine). The company ...

Allergan plcAGN and Hungary-based partner Gedeon Richter Plc. have announced positive top-line results from the third pivotal study, evaluating the companies' schizophrenia drug Vraylar (cariprazine) ...

DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Vraylar" report has been added to ResearchAndMarkets.com's offering. Vraylar (cariprazine; Gedeon Richter/Allergan ...

Allergan’s new campaign for antipsychotic drug Vryalar features two firsts. It’s the first campaign for Vraylar, and it’s the first to feature the manic side of bipolar disorder as the central ...

Allergan plcAGN, along with partner Gedeon Richter, announced positive top-line results from a second pivotal phase III study on its schizophrenia drug Vraylar. The study evaluated Vraylar ...

Please provide your email address to receive an email when new articles are posted on . Allergan recently announced that Vraylar, a once-daily oral atypical antipsychotic, is now available by ...

The U.S. Food and Drug Administration today approved Vraylar (cariprazine) capsules to treat schizophrenia and bipolar disorder in adults. "Schizophrenia and bipolar disorder can be disabling and can ...

Allergan has just announced that their product, Vraylar has been approved by the U.S. Food and Drug Administration (FDA) for use to treat manic or mixed episodes of bipolar 1 and schizophrenia mental ...

The FDA has approved the use of Vraylar (cariprazine; Allergan) to treat depressive episodes associated with bipolar I disorder (bipolar depression) in adults. The Food and Drug Administration (FDA) ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...